Bicara Therapeutics (BCAX) to Release Quarterly Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX) is expected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Bicara Therapeutics to post earnings of ($0.31) per share for the quarter.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX opened at $13.00 on Friday. Bicara Therapeutics has a 52-week low of $11.10 and a 52-week high of $28.09. The business has a 50-day moving average price of $14.40.

Wall Street Analyst Weigh In

BCAX has been the subject of several research reports. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. HC Wainwright boosted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. Finally, Rodman & Renshaw initiated coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective for the company. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Bicara Therapeutics has an average rating of “Buy” and an average target price of $41.20.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.